What does Big Tech hope to gain from warming up to Trump?
GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GCC-4001 overview GCC-4001 (AB-101) is under development for the treatment of rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis, B-cell non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, Waldenstrom Macroglobulinemia, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), R/R classical Hodgkin lymphoma, lupus nephritis (LN) and autoimmune disorders. The therapeutic candidate is an allogeneic, non-engineered, cord blood-derived natural killer (NK) cell therapy. It is administered through intravenous route and is being developed based on AlloNK platform. Artiva Biotherapeutics overview Artiva Biotherapeutics is a biotechnology company developing allogeneic natural killer (NK) cell therapies to treat hematologic cancers or solid tumors. It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric antigen receptor-modified natural killer) cell therapy targeting HER2 positive solid tumors; and AB-202 against CD19 positive B-cell malignancies. Artiva Biotherapeutics utilizes its proprietary CAR (chimeric antigen receptor) platform to improve NK cells’ therapeutic activity and tumor-targeting capability. Artiva Biotherapeutics is headquartered in San Diego, California, the US. For a complete picture of GCC-4001’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .Oleksandr Usyk vs Tyson Fury to have FOURTH judge scoring fight - as 'groundbreaking experiment' confirmed for heavyweight showdown Fury and Usyk will meet in their much anticipated rematch on December 21 Saudi boxing powerbroker Turki Alalshikh announced an AI-judge for the fight The AI-judge will score the fight but the verdict will not impact the final result By MICHAEL PAVITT Published: 13:09 EST, 17 December 2024 | Updated: 14:08 EST, 17 December 2024 e-mail 51 shares 9 View comments Tyson Fury 's rematch against Oleksandr Usyk will be scored by a fourth judge using artificial intelligence , it has been announced. The two heavyweights clashed in one of the biggest fights of all time in May in Saudi Arabia. Usyk became the undisputed heavyweight champion of the world with the Ukrainian awarded victory by a via split decision verdict from the three judges. Ahead of the rematch in Riyadh on Saturday night, Saudi boxing powerbroker Turki Alalshikh announced plans for an additional judge to score the rematch. Alalshikh said the AI-powered judge will score the contest as part of an experiment, but its verdict will not impact the official result. 'For the first time ever, an AI-powered judge will monitor the fight,' Alalshikh said. An AI-powered judge has been announced to score Oleksandr Usyk and Tyson Fury's rematch Saudi boxing powerbroker Turki Alalshikh announced plans for a 'groundbreaking experiment' The AI boxing judge will score the fight but its verdict will not impact the final result of the fight 'Free from bias and human error brought to you by The Ring. 'This groundbreaking experiment, which won’t impact the official results, debuts during the biggest fight of the century, #Usyk2Fury, on December 21. 'Don’t miss history in the making.' Alalshikh shared a video promoting the judge which stated: ‘For years boxing has been defined by its glory but sometimes that glory is clouded by doubt and controversy. Isn’t it time for fairness to step into the ring? The promotion added ‘This isn’t just AI, it’s revolutionizing boxing. It’s fairness powered by technology and human expertise. See the revolution unfold on December 21.’ The first fight saw Usyk awarded the contest by two judges, who scored it 115-112, 114-113 in his favour. The third judge had given Fury the verdict by a 114-113 score. Fury and Usyk will meet in a 12-round rematch at the Kingdom Arena as the Gypsy King seeks to bounce back from his only defeat in professional boxing career. For the first time ever, an AI-powered judge will monitor the fight 🤖 Free from bias and human error brought to you by The Ring. This groundbreaking experiment, which won’t impact the official results, debuts during the biggest fight of the century, #Usyk2Fury , on December 21 🥊... pic.twitter.com/RdslVlBLRC — TURKI ALALSHIKH (@Turki_alalshikh) December 17, 2024 Fury will be hoping to bounce back from the first defeat of his professional boxing career Usyk will put three of his belts on the line when he takes on Fury in the rematch in Riyadh This time around there will be three belts up for grabs, as Usyk has since vacated the IBF belt. Fury claims to have rewatched their first bout 'a hundred times' and will be making some adjustments in a bid to cause Usyk's first defeat of his career in their Riyadh showdown. Fury has maintained that he was actually the victor from the first fight, and claims that he wasn't focused - something he is keen to put right this time. 'I need to be more focused this time and not do as much showboating, he said via GB News. 'That's how easy it was for me and you can get complacent. 'I don't believe the showboating cost me the fight but I need to be more focused this time and not do as much. 'I didn't feel as if I could have knocked him out at any point. I hurt him a few times to the body and with head shots but I didn't feel I was going to take him out.' 'It was my best performance in the last five years, probably more.' HOW TO WATCH: Click to register and watch Usyk vs. Fury 2 on DAZN here Oleksandr Usyk Tyson Fury Share or comment on this article: Oleksandr Usyk vs Tyson Fury to have FOURTH judge scoring fight - as 'groundbreaking experiment' confirmed for heavyweight showdown e-mail 51 shares Add commentThe Kickstarter Campaign of the Lefondat 2-In-1 Airless Paint Sprayer Starts On Dec 17th
UNSW green hydrogen project secures funding for international research collaboration
What does Big Tech hope to gain from warming up to Trump?
Srinagar, Nov 22: In a remarkable achievement for the region, a 22-month-old girl successfully underwent cochlear implant surgery today at Shri Mata Vaishno Devi Narayana Superspeciality Hospital. This milestone marks only the second time in north India that the advanced “SmartNav” electrode insertion monitoring software was utilized during the procedure, heralding a new era in patient care and precision surgery. The surgery was performed by Dr Rohan Gupta, ENT Consultant at Shri Mata Vaishno Devi Narayana Superspeciality Hospital. Alongside that surgery, another cochlear implant procedure was successfully carried out on a two-year-old child. Shri Mata Vaishno Devi Narayana Superspeciality Hospital has been a pioneer in this field, having initiated cochlear implant surgeries in 2017 and successfully treating close to 100 patients, including bilateral implants and cases as young as 14 months old. Dr Rohan Gupta described the SmartNav software as a “game changer,” emphasising its role in enhancing surgical precision, reducing radiation exposure, and improving patient safety. He explained the software’s findings to parents post-surgery, who were overjoyed to see real-time data confirming the successful placement and functionality of the electrodes. Dr M M Mathavan, Facility Director, highlighted that adopting cutting-edge technologies like SmartNav reflects the hospital’s unwavering commitment to delivering world-class healthcare, setting a benchmark in cochlear implant procedures in the region. Dr Yashpal Sharma, Executive Director at the Shri Mata Vaishno Devi Institute of Medical Excellence, expressed pride in the hospital’s achievements and emphasized the Shrine Board’s role in making such advanced treatments available locally. He stated, “Thanks to the Shrine Board’s commitment, families no longer need to leave the state to seek specialized care for their children with hearing loss. Our focus has always been on enabling comprehensive, high-quality care here at home, allowing families to receive the best medical attention without the financial and emotional strain of traveling out of state.” Dr Yashpal Sharma commended the hospital team for their dedication, saying, “With a skilled team and cutting-edge technology, the Cochlear Implant Program at Shri Mata Vaishno Devi Narayana Superspeciality Hospital has become a pillar of hope for families in the region. Our mission is not only to treat hearing loss but also to build a community where every child has the opportunity to thrive. We will continue to set new benchmarks in ENT and cochlear implant surgeries ensuring families have access to the best possible care Dr Rohan Gupta expressed his deep gratitude to Dr Yashpal Sharma, acknowledging his guidance and support. “Dr Yashpal Sharma’s leadership has been crucial in the growth and success of our Cochlear Implant Program. His vision inspires us to keep advancing and to make a difference in the lives of children with hearing loss.” This achievement reinforces Shri Mata Vaishno Devi Narayana Superspeciality Hospital’s position as a leader in cochlear implant surgeries, transforming lives and helping families access world-class healthcare right here in the region.As 2024 closes out, the uranium spot price touches a low point for the year but remains at a higher level than seen in more than a decade, as Japan’s interest in bolstering nuclear energy adds tailwinds to uranium demand. Uranium oxide sat at $77.08 per lb. at the end of November, down 3.6% for that month, and was down 15.38% from the end of last year , though it was up 18.79% over the past three-year period, the $6.6 billion Sprott Physical Uranium Trust (TSX: U.U for USD; U.UN for CAD) noted in its latest report on Friday. “Given the growing sensitivity to geopolitical factors, we believe the uranium price will continue to behave in this staircase-like pattern over the intermediate term with short-term bouts of volatility,” Jacob White, Sprott’s ETF product manager, said in the report. The uranium spot price, which hit $106 per lb. at the end of January, a level not seen in 17 years, gained in the context of the nuclear metal’s supply not meeting rising demand as countries seek greener options for energy generation. Japan warms to nuclear Uranium has been buoyed by growing global support for nuclear energy, with more countries pledging to triple nuclear capacity by 2050, as discussed at the UN’s COP29 climate change conference in Azerbaijan last month. The world’s fourth largest economy, Japan is to seek a 20% increase in nuclear energy usage by 2040, up from 8.5% currently, according to its revised energy policy released on Tuesday, Reuters reported. Its renewed interest in nuclear marks a stark contrast with the country’s reaction to the 2011 Fukushima nuclear disaster, after which it suspended operations at all of its nuclear plants. It began resuming operations four years later. Other renewable energies are to account for 40 to 50% of the total energy mix, up from 23% last year, while the share of fossil fuel use is to drop to 30-40% from 69% by 2040. Japan’s power demand is forecast to rise 20% by 2040 as electrification is expected to increase. Nuclear power is gaining interest in other Asia-Pacific nations as well. Taiwan Premier Cho Jung-tai expressed openness to using new nuclear technologies to meet rising demand from power-hungry chipmakers in the AI industry, according to a Bloomberg report in October. The East Asian country’s policy has been to ease off nuclear power, with plans to close its last reactor in the spring. Vietnam is seeking to amend its national power development plan to accommodate nuclear and hydrogen options, Reuters reported in October. And the Philippines is considering restarting its shuttered Bataan nuclear plant as South Korea’s Korea Hydro & Nuclear Power plans to launch a feasibility study on evaluating the restart, according to World Nuclear News. South Korea itself broke new ground for two new nuclear plants in October under the leadership of pro-nuclear President Yoon Seok-yeol. However, the progress of future nuclear plants there could be stymied if opposition leader Lee Jae-myung, who opposes new nuclear plants, replaces Yoon, currently facing impeachment after a failed martial law attempt. Uranium supply overhang Sprott noted that conversion and enrichment prices are at all-time highs, which highlights the strength of the metal’s current market dynamics. The spot market is also facing pressures of an overhang of supply as some uranium traders seek to clear their positions before the year is over, and rumours that the Kazakh ANU physical uranium fund might liquidate its 2+ million-lb. inventory. “While Russia’s retaliatory export ban on enriched uranium to the US pushes utilities’ focus to the nuclear fuel cycle’s conversion and enrichment segments, we believe this attention will eventually cascade down to uranium oxide,” White wrote. In contrast to the spot price dipping in November, White noted that uranium mining equities gained 1.18% last month, though they were flat for the year. Equities were up 9.15% over the last three years.
Mahindra & Mahindra (OTCMKTS:MAHMF) Shares Up 9.6% – What’s Next?
49ers vs. Bears: Kyle Shanahan provides updates on Nick Bosa, Trent Williams
Friendly reminder |
The authenticity of this information has not been verified by this website and is for your reference only. Please do not reprint without permission. If authorized by this website, it should be used within the scope of authorization and marked with "Source: this website". |
Special attention |
Some articles on this website are reprinted from other media. The purpose of reprinting is to convey more industry information, which does not mean that this website agrees with their views and is responsible for their authenticity. Those who make comments on this website forum are responsible for their own content. This website has the right to reprint or quote on the website. The comments on the forum do not represent the views of this website. If you need to use the information provided by this website, please contact the original author. The copyright belongs to the original author. If you need to contact this website regarding copyright, please do so within 15 days. |